MARK2 and melanoma: The combinatorial effects observed with PDE7A and DHODH inhibitors are consistent with what has been observed in the context of mitogen-activated protein kinase signaling cascade; combination therapy targeting B-Raf proto-oncogene, serine/threonine kinase (BRAF) and MEK has shown superior clinical efficacy compared to monotherapy in BRAF-mutant melanomas.